We strive to help patients with cancer to not only live longer, but live better. For many people on existing therapies, poor drug tolerability can both limit and diminish gains in survival. Additionally, efﬁcacy-related challenges like drug resistance and disease recurrence have emerged, hindering patients’ quality of life and longevity.
We aim to address emerging unmet needs with precision oncology therapeutics that can enhance overall patient well-being. Our drug candidates are designed to push the science, and our strategy is to rapidly advance therapies to patients who need them by incorporating regulatory, clinical development, and commercial input early in R&D.
Through our collaborative approach, we are bringing validated targets into a new light with the goal of enlivening the health and hope of patients with cancer.